Tilray Exports Medical Cannabis Genetics to the EU
In September, Tilray announced plans to invest up to 20 million in a European Union Campus after receiving licences to import genetics and cultivate medical cannabis from the Government of Portugal. To establish the EU Campus, Tilray is investing in multiple facilities located in and around Cantanhede. The EU Campus will include indoor and greenhouse cultivation sites, as well as facilities to process, package, and distribute medical cannabis and cannabinoid-derived medical products. The EU Campus will also serve as a hub supporting Tilrays clinical research and product development efforts across Europe.
Phase one of the project, which is expected to be complete in the first half of 2018, includes an indoor laboratory and genetics bank (completed), a 10,000 m2 greenhouse (under construction), and a 3,000 m2 processing facility (under construction). Subsequent phases, which should be completed by 2020, will add 15,000 m2 of greenhouse cultivation space and another 3,000 m2 for processing.
Tilray is investing aggressively to expand its operations in the European Union in response to considerable unmet need for high-quality medical cannabis. In October, Tilray achieved two other strategic milestones in the EU by becoming the first medical cannabis licensed producer to import full-spectrum medical cannabis extract products into Germany for nationwide distribution through pharmacies and the first licensed medical cannabis producer to sign an agreement with an established pharmaceutical wholesaler. As the first full-spectrum extracts available in Germany, Tilrays products are an important addition to Germanys pharmaceutical market for medical cannabis products. Tilray products are also currently available in the EU member states of Croatia and Cyprus. In the coming months, the company plans to announce additional EU exports and research partnerships.